Search

Jeffrey Mark Dener

from San Mateo, CA
Age ~63
Get Report
Also known as:
Jeffrey M Dener, Jeffrey J Dener, Jeefery Dener
Phone and address:
1948 Vista Cay, San Mateo, CA 94404
(650) 341-7636
Related to:
John Carton, 58Dener Ross, 30Miriam Duncan, 89
Connected to:
Charles A Deneris, 57Nancy S Denero, 78Jan S Deneroff, 73Botond Denes, 43Brian T Denes, 36Christopher B Denes, 68Jean P Denes, 65Jordan M Denes, 33Joseph D Denes, 65Laszlo T Denes, 65

Jeffrey Dener Phones & Addresses

  • 1948 Vista Cay, San Mateo, CA 94404 (650) 341-7636
  • 799 Banbury Ln, Millbrae, CA 94030 (650) 341-7636
  • Daly City, CA
  • Columbus, OH
  • Oakland, CA
  • King of Prussia, PA

Interests

career opportunities, consulting offers,...

Industries

Pharmaceuticals

Resumes

Resumes

Jeffrey Dener Photo 1

Director Of Process Chemistry At Virobay, Inc.

View page
Location:
San Francisco Bay Area
Industry:
Pharmaceuticals
Experience:
ViroBay, Inc. (Privately Held; Pharmaceuticals industry): Director of Process Chemistry,  (November 2006-Present) Expert in the outsourcing and management of both process R&D and manufacture of active pharmaceutical ingredients (APIs) at both US and international contract man...

Business Records

Name / Title
Company / Classification
Phones & Addresses
Jeffrey Dener
Principal
Jmd Chemistry Consulting
Business Consulting Services
799 Banbury Ln, Millbrae, CA 94030

Publications

Us Patents

Process For The Preparation Of (3S)-3-Amino-N-Cyclopropyl-2-Hydroxyalkanamide Derivatives

View page
US Patent:
8143448, Mar 27, 2012
Filed:
Jun 12, 2009
Appl. No.:
12/484078
Inventors:
Jeffrey Dener - Millbrae CA, US
Assignee:
ViroBay, Inc. - Menlo Park CA
International Classification:
C07C 233/05
US Classification:
564193, 564165, 562405, 560 43
Abstract:
The present invention relates to a process for the preparation of (2S,3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamides as well as novel compounds prepared or used in the process.

Process For The Preparation Of (3S)-3-Amino-N-Cyclopropyl-2-Hydroxyalkanamide Derivatives

View page
US Patent:
8431733, Apr 30, 2013
Filed:
Mar 11, 2009
Appl. No.:
12/402312
Inventors:
Jeffrey Dener - Millbrae CA, US
Assignee:
Virobay, Inc. - Menlo Park CA
International Classification:
C07C 229/00
C07C 237/02
US Classification:
562443, 562444, 562450, 564193
Abstract:
The present invention relates to a process for the preparation of (2S,3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamides, and their use in the preparation of HCV inhibitors and cathepsin inhibitors.

Antiviral Agents

View page
US Patent:
20070287699, Dec 13, 2007
Filed:
Apr 30, 2007
Appl. No.:
11/742461
Inventors:
Dange Kumar - Salt Lake City UT, US
Roopa Rai - San Carlos CA, US
Wendy Young - San Mateo CA, US
Huiyong Hu - San Diego CA, US
Jennifer Riggs - Cardiff by the Sea CA, US
Tony Ton - Fremont CA, US
Michael Green - Half Moon Bay CA, US
Barry Hart - Palo Alto CA, US
Kenneth Brameld - San Mateo CA, US
Jeffrey Dener - Millbrae CA, US
Assignee:
ViroBay, Inc. - Menlo Park CA
International Classification:
A61K 31/4709
A61K 31/496
A61K 31/5355
A61K 31/541
A61K 31/551
A61P 31/14
C07D 215/233
C07D 243/08
C07D 279/12
C07D 401/04
C07D 413/04
C07D 455/02
C07D 471/04
US Classification:
514218000, 514228200, 514234500, 514235200, 514253080, 514300000, 514306000, 514312000, 540575000, 544128000, 544238000, 544058200, 546123000, 546138000, 546156000
Abstract:
Compounds are provided having utility for the treatment of viral infections, particularly HCV.

Hcv Inhibitors

View page
US Patent:
20080161254, Jul 3, 2008
Filed:
Jan 2, 2008
Appl. No.:
11/968475
Inventors:
Michael J. Green - Half Moon Bay CA, US
Jeffrey M. Dener - Millbrae CA, US
Assignee:
ViroBay, Inc. - Menlo Park CA
International Classification:
A61K 31/7056
C07D 495/04
A61P 31/12
A61K 31/4365
US Classification:
514 43, 546114, 514301
Abstract:
The present invention is directed to compounds that are antiviral agents. Specifically, the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

Compositions And Methods For Treating Mast-Cell Mediated Conditions

View page
US Patent:
62112287, Apr 3, 2001
Filed:
Mar 29, 1999
Appl. No.:
9/280227
Inventors:
Ken Duane Rice - Palo Alto CA
Jeffrey Mark Dener - Daly City CA
Anthony Robert Gangloff - San Mateo CA
Elaine Yee-Lin Kuo - San Francisco CA
Assignee:
Axys Pharmaceuticals, Inc - South San Francisco CA
International Classification:
A61K 71335
C07C32112
US Classification:
514450
Abstract:
Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.

1,2-Dithiin Antiinfective Agents

View page
US Patent:
55568750, Sep 17, 1996
Filed:
Aug 24, 1995
Appl. No.:
8/110917
Inventors:
Thien V. Truong - Emeryville CA
Donald E. Bierer - Daly City CA
Jeffrey M. Dener - Daly City CA
Richard Hector - Moss Beach CA
Michael S. Tempesta - Moss Beach CA
Bernard Loev - Scarsdale NY
Wu Yang - Ann Arbor MI
Masato Koreeda - Ann Arbor MI
Assignee:
Shaman Pharmaceuticals, Inc. - South San Francisco CA
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
A61K 31385
C07D33908
US Classification:
514436
Abstract:
This invention pertains to a novel group of 1,2-dithiin compounds useful as antiinfective agents, and a novel synthetic process to produce the same. The compounds are particularly effective in treating fungal infections, especially those caused by Candida albicans, Cryptococcus neoformans or Aspergillus fumigatus.

Process For The Preparation Of Mono- And Bis(Phosphocholine) Derivatives Which Have Antifungal Activity

View page
US Patent:
58115684, Sep 22, 1998
Filed:
Apr 28, 1994
Appl. No.:
8/234483
Inventors:
Donald E. Bierer - Daly City CA
Jeffrey M. Dener - Daly City CA
Thien V. Truong - Emeryville CA
Assignee:
Shaman Pharmaceuticals, Inc. - South San Francisco CA
International Classification:
C07F 902
US Classification:
558 87
Abstract:
This invention pertains to a synthetic process for obtaining a unique phosphocholine derivative which has been isolated from the leaves of the plant Irbachia alata, identified to be 1,22-bis�2-(trimethylammonium)ethylphosphatyl! docosane is disclosed. Also disclosed is a synthetic process for obtaining a novel class of mono- and bis(phosphocholine) derivatives which are useful as antiinfective agents. The compounds are particularly effective in treating fungal infections, especially those caused by Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus.

Synthesis Of Optically Active Lactones From L-Aspartic Acid And Intermediates Thereof

View page
US Patent:
53229428, Jun 21, 1994
Filed:
Jun 3, 1991
Appl. No.:
7/709373
Inventors:
Henry Rapoport - Berkeley CA
Jeffrey M. Dener - King of Prussia PA
Assignee:
Regents of the University of California - Oakland CA
International Classification:
C07D23920
C07D30733
US Classification:
544297
Abstract:
Optically active lactones are described, such as an intermediate lactone having the formula ##STR1## where R and R. sup. 2 are each independently alkyl with 1 to 6 carbon atoms, cycloalkyl with 6 to 10 carbon atoms, aryl with 6 to 10 carbon atoms, or arylalkyl with 7 to 19 carbon atoms, R. sup. 4 is H or C. sub. 1-6 alkyl, and Ar is a homo- or heteroaromatic ring with 5 or 6 ring atoms being optionally substituted by C. sub. 1-6 alkyl or alkoxy groups, halogen atoms, cyano or nitro groups. Such optically active, intermediate lactones are prepared from L-aspartic acid, and can be readily converted to (+)-pilocarpine and its analogues by hydrolysis, reduction, and hydrogenation, such as to an optically active lactone having the formula ##STR2## which is (+)-pilocarpine when R is ethyl, R. sup. 4 is H, and Ar is 1-methylimidazol-5-yl.
Control profile
Jeffrey Mark Dener from San Mateo, CA, age ~63 Get Report